Using advances in genetic sequencing and artificial intelligence, a dozen or more companies are working on blood tests, sometimes called liquid biopsies, that can pick up cancer signals circulating in minuscule concentrations in the bloodstream. The demand for these tests, if they end up being useful, is enormous. According to estimates by the nonprofit think tank Information Technology and Innovation Foundation, the potential market for this kind of cancer-detection technology is worth more than $6 billion and is expected to almost triple in value by 2025.
